Editor's Note
The Centers for Medicare and Medicaid Services (CMS) on November 10 announced that Medicare will cover out-of-pocket costs for monoclonal antibody drugs for COVID-19 during the public health emergency.
The agency’s coverage includes Eli Lilly’s bamlanivimab, which recently received an emergency use authorization from the Food and Drug Administration.
Medicare won’t pay for monoclonal antibody products that providers receive for free, but it will pay for the infusion.
Free Daily News